Table 1.

Baseline characteristics of enrolled patients, grouped according to therapya (n = 201)

7.5% Icodextrin Group (ICO)2.5% Glucose Group (GLU)P Value
N98103
Age (yr old)56.8 ± 13.555.4 ± 14.00.42
Male/female51/4745/580.24
CAPD duration (m)28.2 ± 24.929.8 ± 26.00.72
eGFR (ml/min)2.38 ± 2.052.26 ± 2.260.66
Blood Cr concentration (umol/L)997.7 ± 313.6989.10 ± 297.160.89
Blood BUN concentration (mmol/L)20.11 ± 6.8220.47 ± 5.540.57
Net ultrafiltration volume in long dwell (ml)235.92 ± 246.48267.96 ± 239.270.38
Long-term Peritoneal Ccr (ml/min)2.97 ± 0.723.16 ± 0.860.06
Peritoneal transport character (PET)0.35
    high, n (%)9 (9.2)15 (14.6)
    high-average, n (%)39 (39.8)33 (32.0)
    low-average, n (%)35 (35.7)46 (44.7)
    low, n (%)14 (14.3)7 (6.8)
Primary ethiology of kidney disease0.16
    chronic glomerulonephritis, n (%)41 (41.8)37 (35.9)
    diabetic nephropathy, n (%)24 (24.5)21 (20.4)
    hypertension, n (%)14 (14.3)13 (12.6)
    others, n (%)19 (19.3)32 (31.1)
  • a All the patients received 2.5% Dianeal® PD-2 or PD-4 dialysate in long dwell time in baseline.

  • Values are expressed as mean ± SEM; CAPD, continuous ambulatory peritoneal dialysis; eGFR, estimated glomerular filtration rate; PET, peritoneal equilibration test; ESRF, end stage renal failure.